Molecular classification of hormone-sensitive and castration-resistant prostate cancer, using nonnegative matrix factorization molecular subtyping of primary and metastatic specimens.
CRPC
HSPC
TME
molecular subtyping
Journal
The Prostate
ISSN: 1097-0045
Titre abrégé: Prostate
Pays: United States
ID NLM: 8101368
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
revised:
12
02
2022
received:
23
09
2021
accepted:
14
03
2022
pubmed:
19
4
2022
medline:
14
5
2022
entrez:
18
4
2022
Statut:
ppublish
Résumé
Despite the rapidly evolving therapeutic landscape, immunotherapy has demonstrated limited activity in prostate cancer. A greater understanding of the molecular landscape, particularly the expression of immune-related pathways, will inform future immunotherapeutic strategies. Consensus nonnegative matrix factorization (cNMF) is a novel model of molecular classification analyzing gene expression data, focusing on biological interpretation of metagenes and selecting meaningful clusters. We aimed to identify molecular subtypes of prostate cancer using cNMF and correlate these with existing biomarkers to inform future immunotherapeutic strategies. A cohort of archival tumor specimens from hormone-sensitive and castration-resistant disease was studied. Whole transcriptomic profiles were generated using TruSeq RNA Access technology and subjected to cNMF. Comprehensive genomic profiling was performed with the FoundationOne assay. NMF subtypes were characterized by gene expression pathways, genomic alterations and correlated with clinical data, then applied to The Cancer Genome Atlas data set. We studied 164 specimens, including 52 castration-resistant and 13 paired primary/metastatic specimens. cNMF identified four distinct subtypes. NMF1 (19%) is enriched for immune-related and stromal-related pathways with transforming growth factor β (TGFβ) signature. NMF2 (36%) is associated with FOXO-mediated transcription signature and AKT signaling, NMF3 (26%) is enriched for ribosomal RNA processing, while NMF4 (19%) is enriched for cell cycle and DNA-repair pathways. The most common gene alterations included TMPRSS22 (42%), TP53 (23%), and DNA-repair genes (19%), occurring across all subtypes. NMF4 is significantly enriched for MYC and Wnt-signaling gene alterations. TMB, CD8 density, and PD-L1 expression were low overall. NMF1 and NMF4 were NMF2 was associated with superior overall survival. Using cNMF, we identified four molecularly distinct subtypes which may inform treatment selection. NMF1 demonstrates the most inflammatory signature with asuppressive TGFβ signature, suggesting potential benefit with immunotherapy combination strategies targeting TGFβ and PD-(L)1. Prospective studies are required to evaluate the use of this novel model to molecularly stratify patients for optimal treatment selection.
Sections du résumé
BACKGROUND
Despite the rapidly evolving therapeutic landscape, immunotherapy has demonstrated limited activity in prostate cancer. A greater understanding of the molecular landscape, particularly the expression of immune-related pathways, will inform future immunotherapeutic strategies. Consensus nonnegative matrix factorization (cNMF) is a novel model of molecular classification analyzing gene expression data, focusing on biological interpretation of metagenes and selecting meaningful clusters.
OBJECTIVE
We aimed to identify molecular subtypes of prostate cancer using cNMF and correlate these with existing biomarkers to inform future immunotherapeutic strategies.
METHODS
A cohort of archival tumor specimens from hormone-sensitive and castration-resistant disease was studied. Whole transcriptomic profiles were generated using TruSeq RNA Access technology and subjected to cNMF. Comprehensive genomic profiling was performed with the FoundationOne assay. NMF subtypes were characterized by gene expression pathways, genomic alterations and correlated with clinical data, then applied to The Cancer Genome Atlas data set.
RESULTS
We studied 164 specimens, including 52 castration-resistant and 13 paired primary/metastatic specimens. cNMF identified four distinct subtypes. NMF1 (19%) is enriched for immune-related and stromal-related pathways with transforming growth factor β (TGFβ) signature. NMF2 (36%) is associated with FOXO-mediated transcription signature and AKT signaling, NMF3 (26%) is enriched for ribosomal RNA processing, while NMF4 (19%) is enriched for cell cycle and DNA-repair pathways. The most common gene alterations included TMPRSS22 (42%), TP53 (23%), and DNA-repair genes (19%), occurring across all subtypes. NMF4 is significantly enriched for MYC and Wnt-signaling gene alterations. TMB, CD8 density, and PD-L1 expression were low overall. NMF1 and NMF4 were NMF2 was associated with superior overall survival.
CONCLUSIONS
Using cNMF, we identified four molecularly distinct subtypes which may inform treatment selection. NMF1 demonstrates the most inflammatory signature with asuppressive TGFβ signature, suggesting potential benefit with immunotherapy combination strategies targeting TGFβ and PD-(L)1. Prospective studies are required to evaluate the use of this novel model to molecularly stratify patients for optimal treatment selection.
Identifiants
pubmed: 35435276
doi: 10.1002/pros.24346
pmc: PMC9321082
doi:
Substances chimiques
Biomarkers, Tumor
0
Hormones
0
Transforming Growth Factor beta
0
DNA
9007-49-2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
993-1002Informations de copyright
© 2022 The Authors. The Prostate published by Wiley Periodicals LLC.
Références
Nat Biotechnol. 2013 Nov;31(11):1023-31
pubmed: 24142049
Prostate. 2021 Jan;81(1):50-57
pubmed: 32986884
J Clin Oncol. 2020 Feb 10;38(5):395-405
pubmed: 31774688
Ann Oncol. 2018 Aug 1;29(8):1807-1813
pubmed: 29992241
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Prostate. 2022 Jun;82(9):993-1002
pubmed: 35435276
Genome Biol. 2017 Nov 15;18(1):220
pubmed: 29141660
Oncotarget. 2018 Jun 19;9(47):28561-28571
pubmed: 29983880
Nature. 2018 Feb 22;554(7693):544-548
pubmed: 29443960
JAMA Oncol. 2019 Apr 01;5(4):471-478
pubmed: 30589920
Lancet. 2016 May 7;387(10031):1909-20
pubmed: 26952546
Proc Natl Acad Sci U S A. 2004 Mar 23;101(12):4164-9
pubmed: 15016911
Nature. 1999 Oct 21;401(6755):788-91
pubmed: 10548103
Genome Res. 2003 Jul;13(7):1706-18
pubmed: 12840046
Lancet Oncol. 2020 Oct;21(10):1353-1365
pubmed: 32919526
PLoS One. 2016 Aug 03;11(8):e0159109
pubmed: 27487262
Clin Cancer Res. 2014 Oct 1;20(19):5064-74
pubmed: 24714771
Proc Natl Acad Sci U S A. 2004 Jan 20;101(3):811-6
pubmed: 14711987
Nucleic Acids Res. 2011 Jan;39(Database issue):D945-50
pubmed: 20952405
J Clin Oncol. 2009 Mar 10;27(8):1160-7
pubmed: 19204204
Clin Cancer Res. 2016 Apr 15;22(8):1969-77
pubmed: 26573597
Annu Rev Med. 2019 Jan 27;70:479-499
pubmed: 30691365
Proc Natl Acad Sci U S A. 2011 Dec 27;108(52):21276-81
pubmed: 22123976
Cancer Res. 2016 Sep 1;76(17):4948-58
pubmed: 27302169
JCO Precis Oncol. 2020;4:370-381
pubmed: 32462107
Genome Biol. 2016 Oct 20;17(1):218
pubmed: 27765066
Cell. 2019 Nov 14;179(5):1177-1190.e13
pubmed: 31730856
Front Oncol. 2015 Jul 08;5:128
pubmed: 26217583
Ann Oncol. 2019 Jan 1;30(1):44-56
pubmed: 30395155
Prostate. 2021 Jan;81(1):20-28
pubmed: 33085799
Trends Immunol. 2010 Jun;31(6):220-7
pubmed: 20538542
JAMA Oncol. 2017 Dec 1;3(12):1663-1672
pubmed: 28494073
Anal Cell Pathol. 2001;23(1):29-37
pubmed: 11790857
Cell. 2015 Nov 5;163(4):1011-25
pubmed: 26544944
Cancers (Basel). 2021 Jan 19;13(2):
pubmed: 33477882
Prostate Cancer Prostatic Dis. 2015 Dec;18(4):325-32
pubmed: 26260996
Cell. 2015 Jul 16;162(2):454
pubmed: 28843286
Mol Oncol. 2021 May;15(5):1358-1375
pubmed: 33338321